3:38 PM
 | 
Jun 13, 2018
 |  BC Extra  |  Company News

Management tracks: Salk Institute, Galectin

The Board of Trustees for the Salk Institute for Biological Studies (La Jolla, Calif.) said that cancer and gene therapy researcher Inder Verma has resigned. The institute had placed Verma on administrative leave in April pending investigation following allegations of sexual harassment.

Allergy company Aimmune Therapeutics Inc. (NASDAQ:AIMT) hired Jayson Dallas as president and CEO. He was chief commercial officer at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said Luc Debruyne will step down as president of...

Read the full 375 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >